Mounjaro for Weight Loss
Eli Lilly's weekly injection for type 2 diabetes. Mounjaro is the same drug as Zepbound (tirzepatide), but labeled for diabetes rather than weight loss.
Reviewed by GlobalGLP1 editorial team • Drug facts last checked August 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Jump to a section
Overview
Mounjaro is a once-weekly injection from Eli Lilly that was FDA-approved in May 2022 to treat type 2 diabetes. It is the first medication in a new class that activates two hormones (GIP and GLP-1), which in clinical trials produced stronger blood sugar and weight effects than older GLP-1-only drugs like Ozempic. Mounjaro uses the same active ingredient (tirzepatide) as Zepbound, which is the version approved for weight loss. Mounjaro is FDA-approved only for type 2 diabetes in adults. It is not approved for weight loss, and insurance almost never covers off-label prescribing.
How Mounjaro Works
Mounjaro works by activating two hunger-related hormones at once: GIP and GLP-1. Most older medications only target one. By hitting both, Mounjaro reduces appetite, slows digestion, helps the pancreas release insulin after meals, and improves how your body handles blood sugar. You take it as a once-weekly shot (usually in the belly, thigh, or upper arm). This dual approach is why Mounjaro tends to produce stronger blood sugar and weight effects than single-hormone medications.
FDA Approval
Mounjaro
Type 2 diabetes mellitus
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
How You Take It
Each dose step lasts at least 4 weeks. The slow build-up reduces stomach side effects. Many people get good diabetes control at 5 mg or 7.5 mg without needing the highest doses.
How Much Weight You Can Lose
In diabetes trials, people on Mounjaro 15 mg lost about 12% of their body weight, which is more than most diabetes medications. In the weight loss trials for the same drug (sold as Zepbound), people without diabetes lost about 22.5%. People with diabetes typically lose less weight on GLP-1s than people without diabetes. If weight loss is your primary goal and you do not have diabetes, ask your doctor about Zepbound instead.
Blood sugar effect: Typical A1C drop of 2.0 to 2.4 points (the strongest of any injectable diabetes medication)
Side Effects
Common Side Effects
- Nausea (about 29% of users at the 15 mg dose in SURMOUNT-1; usually worst during dose increases and eases over time)
- Diarrhea (about 23% of users; typically mild and short-lived)
- Decreased appetite (common; this is part of how the drug works)
- Vomiting (about 13% of users; tends to drop off after the first month or two)
- Constipation (about 12% of users)
- Abdominal pain (about 10% of users; usually mild)
- Indigestion / upset stomach (about 9% of users)
- Injection site reactions (uncommon; mild redness near the shot)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, rodent studies)
- Hypoglycemia (with insulin or sulfonylureas)
- Severe GI events
- Allergic reactions including anaphylaxis
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Worsening of diabetic eye disease in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Managing side effects: Similar pattern to semaglutide: stomach-related side effects show up most during the first few weeks and around dose increases, then ease as your body adjusts. The slow dose build-up exists for this reason. Eating smaller, more frequent meals and avoiding high-fat foods help. If vomiting is persistent or severe, contact your provider. They can slow or pause the dose escalation.
Mounjaro Cost & Savings (2026)
Savings programs: Mounjaro Savings Card: commercially insured patients with type 2 diabetes can pay as little as $25/month for a 1 or 3-month prescription, with a maximum annual benefit. Medicare, Medicaid, and cash-paying patients are not eligible. Lilly Cares Patient Assistance Program may provide Mounjaro for free for qualifying uninsured patients with type 2 diabetes who meet income limits. LillyDirect Self Pay: Lilly lists Mounjaro starting at $499 a month at every dose from 2.5 mg to 15 mg, with a prescription required and other terms applying.
Who Should Not Take Mounjaro
- Personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to tirzepatide or any ingredient in the medication
- Pregnancy or planning to become pregnant (stop at least 1 month before conception)
- Severe stomach or intestinal disease
What to Expect, Month by Month
Noticeable decrease in hunger and food noise. Some patients report reduced cravings for high-calorie foods specifically.
Consistent weight loss begins during dose escalation. Average 3-5% body weight lost. Dual GIP/GLP-1 action accelerates early results.
Approaching maintenance dose (10-15 mg). Steady 1-2.5 lbs per week loss. Blood sugar improvements prominent.
Average 15-20% body weight lost. Dramatic improvements in metabolic health markers, blood pressure, and lipids.
Weight loss plateau at 20-22.5% average. Some patients achieve 25%+ loss. Maintenance phase with sustained metabolic benefits.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will likely reduce your insulin dose by 20 to 50% when starting tirzepatide, and may also lower your sulfonylurea dose.
Because tirzepatide slows digestion, pills you take by mouth may absorb differently. This is most noticeable during the first few months when dose changes are happening and stomach effects are strongest.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting or changing your tirzepatide dose.
The FDA label tells prescribers to advise anyone on birth control pills to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase. In testing, tirzepatide cut peak blood levels of the hormones in a combined pill by more than half. Tirzepatide may cause fetal harm. Methods that are not swallowed, such as the patch, ring, implant, injection or IUD, are not affected.
Special Situations
Do not use during pregnancy; the label says to stop as soon as a pregnancy is known. Unlike semaglutide, whose label sets a two-month gap before trying to conceive, the tirzepatide label sets no such period, so ask your prescriber how long to stop beforehand. Animal studies showed harm to the fetus at high doses.
No dose change needed at any level, including end-stage kidney disease, where blood levels of tirzepatide were unchanged. Still watch for dehydration from nausea and vomiting, which can worsen kidney function on its own.
No dose change needed at any level. Blood levels of tirzepatide did not change in people with liver impairment.
No dose change needed. The Zepbound trials included 226 people aged 65 or older, 13 of them 75 or older. Slower dose increases may help reduce stomach side effects in older adults.
Not yet FDA-approved for adolescents. Clinical trials in teens (SURMOUNT-TEENS) are in progress. Some doctors prescribe it off-label for teens with severe obesity.
What Happens If You Stop
In the SURMOUNT-4 trial, people who stopped tirzepatide after 36 weeks regained about two-thirds of the weight they had lost over the following year. People who stayed on it continued to lose weight. This is why most doctors recommend staying on treatment long-term if it is working.
How to make stopping easier: Building healthy eating habits and regular exercise while on the medication is the best insurance against regain. Some doctors are exploring lower maintenance doses to keep weight off at lower cost. Start planning your long-term approach before stopping.
Mounjaro FAQs
No. Mounjaro is only FDA-approved for type 2 diabetes. The same drug (tirzepatide) is approved for weight loss, but it is sold as Zepbound. Some doctors prescribe Mounjaro off-label for weight loss, but insurance almost never covers off-label use, and the Mounjaro savings card requires a type 2 diabetes diagnosis. If weight loss is your main goal and you do not have diabetes, ask your doctor about Zepbound instead.
They are the exact same drug (tirzepatide) at the exact same doses. The only differences are the label and the box. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight loss. Your doctor will prescribe whichever one matches your condition, and your insurance will almost always only cover the one that fits your diagnosis.
Lilly lists Mounjaro at $1,112.16 per fill (its price to wholesalers, WAC as of January 1, 2026), and defines one fill as a month’s supply, which is four pens. Most cash-paying patients do not pay that. Lilly now publishes a self-pay price for Mounjaro on LillyDirect: starting at $499 a month, listed at every approved dose from 2.5 mg through 15 mg, with terms and a prescription required. If you need tirzepatide for weight loss and do not have type 2 diabetes, Zepbound through LillyDirect Self Pay is the cheaper route to the same molecule at the same doses from the same manufacturer, at $299 to $699 for a 28-day supply by dose. Check the current figure with LillyDirect before you budget on either one.
If you have commercial insurance and a type 2 diabetes diagnosis, the Mounjaro Savings Card lets you pay as little as $25/month for a 1 or 3-month prescription, with an annual cap on total savings. Most commercial plans cover Mounjaro for diabetes with prior authorization. Medicare Part D plans also cover it for diabetes, though cost-sharing varies. Medicare and Medicaid patients are not eligible for the savings card.
In diabetes trials (SURPASS), people on Mounjaro 15 mg lost about 12% of their body weight on average, which is still more than most GLP-1s. In the weight loss trials for the same drug (sold as Zepbound under the SURMOUNT program), people without diabetes on the 15 mg dose lost about 22.5% on average. People with diabetes typically lose less weight on GLP-1s than people without diabetes. Results vary a lot from person to person.
You need a prescription from a licensed doctor or nurse practitioner, and a type 2 diabetes diagnosis for insurance to cover it. Many telehealth clinics specialize in GLP-1 prescribing for diabetes and can handle the prior authorization paperwork your insurance usually requires. Use the directory below to compare clinics in your state.
The most common side effects are stomach-related: nausea, diarrhea, vomiting, constipation, and stomach pain. They usually show up when you first start or move up to a higher dose, and most people find they get better after a few weeks. Rare but more serious risks include inflammation of the pancreas, gallbladder problems, low blood sugar (especially when combined with insulin or sulfonylureas), and a warning about thyroid tumors (seen in animal studies, not confirmed in humans). Always tell your doctor about your full medical history before starting.
Find Clinics Offering Mounjaro
Compare Mounjaro providers by pricing, telehealth availability, and patient ratings.
Search Mounjaro Clinics →Related Mounjaro resources
Find Mounjaro Clinics by State
Ready to start Mounjaro?
Search our directory of 3,318 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
References
Every figure on this page comes from one of the following. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Mounjaro (tirzepatide) injection: prescribing information
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) The 72-week weight-loss trial behind the ~21-22.5% figures.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) 731 patients; the basis of the heart-failure figures.
Drug facts on this page last checked against these sources August 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.